Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Lung Transplant Recipients With BOS
NCT03283007Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2019
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bronchiolitis Obliterans Syndrome (BOS) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Rate of decline of Forced Expiratory Volume in 1 second at 6 months. Started Oct 2019; status: completed.
02
Drugs
nintedanib
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT03283007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283007.